Assessing Health State Utilities in Elderly Patients at Cardiovascular Risk

Wolfgang C. Winkelmayer, Joshua S. Benner, Robert J. Glynn, Sebastian Schneeweiss, Philip S. Wang, M. Alan Brookhart, Raisa Levin, Joseph D. Jackson and Jerry Avorn
Additional contact information
Wolfgang C. Winkelmayer: Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, Boston, wwinkelmayer@partners.org
Joshua S. Benner: Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, Boston
Robert J. Glynn: Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, Boston
Sebastian Schneeweiss: Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, Boston
Philip S. Wang: Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, Boston
M. Alan Brookhart: Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, Boston
Raisa Levin: Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, Boston
Joseph D. Jackson: Bristol-Myers Squibb, Princeton, New Jersey
Jerry Avorn: Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, Boston

Medical Decision Making, 2006, vol. 26, issue 3, 247-254

Abstract: Background . Health state preferences can be a crucial component of cost-effectiveness analyses, but off-the-shelf health state utilities specifically for older people are not available. Objectives . Among participants in PROSPER, a trial of pravastatin in patients > 70 years, the authors assessed utilities for the health states that were relevant for the trial’s cost-utility analysis. Subjects and Methods . The authors cross-sectionally administered the Health Utilities Index, Mark 3 (HUI) to all PROSPER participants to assess each patient’s health state at the time of interview; they then used the scale’s multiattribute utility function to estimate the resulting utilities. The population was then stratified into 3 health states, and the mean utility function for each was calculated: recent myocardial infarction (MI, within 3 months), previous MI ( > 3 months), or no prior MI. Linear and logistic regression were used to control for potential demographic and clinical characteristics. Results . Of the 5804 patients enrolled in the trial, 4677 were administered the HUI instrument. The likelihood of having a complete HUI response set decreased with higher age ( P 3 months previously, and 89 (2.6%) had an MI within 3 months. The mean (median) utilities were virtually identical for these states: 0.75 (0.84), 0.74 (0.84), and 0.74 (0.84), respectively. From multivariate analyses, utilities decreased with higher age and the presence of several other comorbidities (diabetes, stroke, peripheral vascular disease); women had lower utilities than men (all P

Keywords: clinical trials; myocardial infarction; pravastatin; health-related quality of life; utility assessment (search for similar items in EconPapers)
Date: 2006
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/0272989X06288685 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:medema:v:26:y:2006:i:3:p:247-254

DOI: 10.1177/0272989X06288685

Access Statistics for this article

More articles in Medical Decision Making
Bibliographic data for series maintained by SAGE Publications ().